Cost effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of scalp psoriasis in Scotland

References

• Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006;10:1
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom. A population-based study. Arch Dermatol 2005;141:1537-41
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Steegers-Theunissen RP, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology 1998;197:31-6
   PubMed Web of Science ®Google Scholar
• Van de Kerkhof PC, de Hoop D, de Korte J, et al. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology 1998;197:326-34
   PubMed Web of Science ®Google Scholar
• Farber EM, Nall L. Natural history and treatment of scalp psoriasis. Cutis 1992;49:396-400
   PubMed Web of Science ®Google Scholar
• Bardazzi F, Fanti PA, Orlandi C, et al. Psoriatic scarring alopecia: observations in four patients. Int J Dermatol 1999;38:765-8
   PubMed Web of Science ®Google Scholar
• Poyner TF, Fell PJ. A survey of patients with plaque psoriasis who had not consulted their doctor in the past year. Br J Clin Res 1995;6:201-7
   Google Scholar
• Lundberg L, Johannesson M, Silverdahl M, et al. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999;141:1067-75
   PubMed Web of Science ®Google Scholar
• Chen SC, Yeung J, Chren MM. Scalpdex: a quality of life instrument for scalp dermatitis. Arch Dermatol 2002;138:803-7
   PubMed Web of Science ®Google Scholar
• Chan CS, van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation. Am Acad Dermatol 2009;60:962-71
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-16
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7
   PubMed Web of Science ®Google Scholar
• Wahl A, Loge JH, Wiklund I, et al. The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms. J Am Acad Dermatol 2000;43:803-8
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Reboussin D, et al. Predictors of health-related quality of life in psoriasis and a comparison with other chronic diseases. Qual Life Res 1997;6:705
   Web of Science ®Google Scholar
• Finlay AY, Khan GK, Luscombe DK, et al. Validation of sickness impact profile and psoriasis disability index in psoriasis. Br J Dermatol 1990;123:751-6
   PubMed Web of Science ®Google Scholar
• Schmitt J, Meuer M, Klon M, et al. Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. Br J Dermatol 2008;158:351-9
   PubMed Web of Science ®Google Scholar
• Dotterud LK, Braun R. [UV-B comb versus betamethasone solution in scalp psoriasis]. Tidsskr Nor Laegeforen 2000;120:1858-9
   PubMedGoogle Scholar
• Braun R, Dotterud LK, Falk ES. Comparison of betamethasone valerate solution with phototherapy (UVB comb) in scalp psoriasis treatment. Acta Derm Venereol 1998;78:385
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Franssen ME. Psoriasis of the scalp. Diagnosis and management. Am J Clin Dermatol 2001;2:159-65
   PubMedGoogle Scholar
• Gottlieb AB. Psoriasis. Dis Manag Clin Outcomes 1998;1:195-202
   Google Scholar
• Koo J. Current consensus and update on psoriasis therapy: a perspective from the U.S. J Dermatol 1999;26:723-33
   PubMedGoogle Scholar
• Lebwohl M. A clinician’s paradigm in the treatment of psoriasis. J Am Acad Dermatol 2005;53:S59-69
   PubMed Web of Science ®Google Scholar
• Richards HL, Fortune DG, O’Sullivan TM, et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999;41:581-3
   PubMed Web of Science ®Google Scholar
• Feldman SR, Housman TS. Patients’ Vehicle Preference for Corticosteroid Treatments of Scalp Psoriasis. Am J Clin Dermatol 2003;4:221-4
   PubMed Web of Science ®Google Scholar
• Papp K, Berth-Jones, J, Kragballe K, et al. Scalp psoriasis: a review of current topical treatment options. J Eur Acad Dermatol Venereal 2007;21:1151-60
   PubMed Web of Science ®Google Scholar
• Buckley C, Hoffmann V, Shapiro J, et al. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology 2008;217:107-13
   PubMed Web of Science ®Google Scholar
• Jemec GBE, Ganslandt C, Ortonne JP, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: A randomized, double-blind, controlled trial. J Am Acad Dermatol 2008;59:455-63
   PubMed Web of Science ®Google Scholar
• Van de Kerkhof P, Hoffmann V, Anstey A, et al. A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Br J Dermatol 2009;160:170-6
   PubMed Web of Science ®Google Scholar
• Kragballe K, Hoffmann V, Ortonne JP, et al. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis. Br J Dermatol 2009;161:159-66
   PubMed Web of Science ®Google Scholar
• Tyring S, Appell M, Bibby A, et al. Calcipotriene/betamethasone dipropionate gel compared to gel vehicle in treating scalp psoriasis in Hispanic/Latino and black/African American patients. J Am Acad Dermatol 2008;58(2 Suppl 2):AB125
   Web of Science ®Google Scholar
• Tyring S, Appell M, Bibby A, et al. A calcipotriene/betamethasone dipropionate two-compound scalp formulation (Taclonex scalp™, Xamiol™) in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomised, 8 week, double-blind phase of a clinical trial. Manuscript accepted by Archives in Dermatology
   Google Scholar
• Luger TA, Cambazard F, Larsen FG, et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology 2008;217:321-8
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Ganslandt C, Tan J, et al. Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. J Eur Acad Dermatol Venereol 2009; 23:919-26
   PubMed Web of Science ®Google Scholar
• Bergstrom KG, Arambula K, Kimball AB. Medication formulation affects QOL: a randomised single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis 2003;72:407-11
   PubMed Web of Science ®Google Scholar
• Van de Kerkhof PC. The impact of two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. Br J Dermatol 2004;151:663-8
   PubMed Web of Science ®Google Scholar
• Kreuger GC, Langley RG, Finlay AY, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 2005;153:1192-9
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate to severe psoriasis: a randomized controlled trial. Br J Dermatol 2006;154:1161-8
   PubMed Web of Science ®Google Scholar
• Revicki D, Williams MK, Saurat JH, et al. Impact of adalimumab treatment on health-related quality of life and other patient reported outcomes: results from a 16-week randomised controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008;158:549-57
   PubMed Web of Science ®Google Scholar
• Touw CR, Hakkaart-van Roijen L, Verboom P, et al. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001;144:967-72
   PubMed Web of Science ®Google Scholar
• LEO Pharma. Dovonex® scalp solution. Summary of Product Characteristics. October 2008
   Google Scholar
• Julian CG. Dermatology in general practice. Br J Dermatol 1999;141:518-20
   PubMed Web of Science ®Google Scholar
• Skincare Conditions in Scotland: What the Healthcare Professionals think. A report of a survey of service provision for patients with dermatological conditions. October 2008. SSCIG, The Scottish Skincare Conditions Industry Group. Available at: http://www.abpi.org.uk/Scotland/pdf/SSCIGSurveyFinalReportOct08.pdf [Accessed on 18 June 2010]
   Google Scholar
• Atopic eczema, psoriasis and acne: common chronic skin conditions that constitute a burden to general practice. A briefing paper prepared by Professor Carol Black, Professor David Gawkrodger and Dr Mark Goodfield on behalf of the Joint Specialty Committee for Dermatology. 14 February 2005. Available at: http://www.skincarecampaign.org/pages/SkinCareCampaignPolicy.htm [Accessed 10 June 2010]
   Google Scholar
• Imison C, Naylor C. Referral management. Lessons for success. 12 August 2010. The Kings Fund. Available at http://www.kingsfund.org.uk/publications/referral_management.html (Accessed 18 August 2010)
   Google Scholar
• NICE. Etanercept and efalizumab for the treatment of adults with psoriasis. NICE technology appraisal guidance 103. July 2006. Available at http://guidance.nice.org.uk/TA103/Guidance/pdf/English [last accessed 19 September 2010]
   Google Scholar
• Oh, PI, Gupta AK, Einarson TR, et al. Calcipotriol in the treatment of psoriasis of limited severity: Pharmacoeconomic evaluation. J Cutaneous Med Surg 1997;2:7-15
   Google Scholar
• Marchetti A, LaPensee K, An P. A pharmacoeconomic analysis of topical therapies for patients with mild to moderate stable plaque psoriasis: a US study. Clinical Therapeutics 1998;20:851-69
   PubMed Web of Science ®Google Scholar
• Ashcroft DM, Po AL, Williams HC, et al. Cost effectiveness analysis of topical calcipotriol versus short-contact dithranol. Pharmacoeconomics 2000;18:469-76
   PubMed Web of Science ®Google Scholar
• Bottomley JM, Auland ME, Morais J, et al. Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland. Curr Med Res Opin 2007;23:1887-901
   PubMed Web of Science ®Google Scholar
• Smith DRW, Bottomley JM, Auland M, et al. Heterogeneity in the treatment of moderately severe scalp psoriasis in Scotland – results of a survey of Scottish health professionals. Curr Med Res Opin 2011;27:239-49
   Google Scholar
• Bottomley JM, Taylor RS, Ryttov J. The effectiveness of two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of moderately severe scalp psoriasis: a systematic review of direct and indirect evidence. Curr Med Res Opin 2011;27:251-68
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP): Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. EMEA, London 18 November 2004: Available at http://www.emea.europa.eu/pdfs/human/ewp/245402en.pdf [Accessed 29 March 2010]
   Google Scholar
• Klaber MR, Hutchinson PE, Pedvis-Leftick A, et al. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis. Br J Dermatol 1994;131:678-83
   PubMed Web of Science ®Google Scholar
• Clinical Study Report. Calcipotriol scalp solution II in psoriasis. Efficacy and Safety of calcipotriol scalp solution II in scalp psoriasis. A multicentre, prospective, randomized, double-blind, vehicle-controlled, comparative study with 3 parallel groups: calcipotriol scalp solution II 50 µg/ml, calcipotriol scalp solution 50 µg/ml and vehicle of scalp solution II. MCW 9603 INT Study. 10 July 2000. LEO Laboratories – DATA ON FILE
   Google Scholar
• Barrett C, Lowson D, Blades KJ, et al. Limited benefit of combined use of tar-based shampoo with 50 µg/ml calcipotriol solution in scalp psoriasis. J Dermatol Treat 2005;16:175
   PubMed Web of Science ®Google Scholar
• Klaber MR, McKinnon C. Calcipotriol (Dovonex) scalp solution in the treatment of scalp psoriasis: comparative efficacy with 1% coal tar/1% coconut oil/0.5% salicylic acid (Capasal) shampoo, and long-term experience. J Dermatol Treat 2000;11:21-8
   Web of Science ®Google Scholar
• NICE Guide to the methods of technology Appraisal (NICE June 2008). Available at http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf [Accessed on 29 March 2010]
   Google Scholar
• Freeman K, Marum M, Bottomley JM, et al. A psoriasis-specific model to support decision-making in practice – UK experience. Curr Med Res Opin 2011;27:205-23
   Google Scholar
• Scottish Medicines Consortium. Calcipotriol and betamethasone dipropionate, 50 micrograms/g + 500 microgram/g gel (Xamiol®). No. 559/09. 10 July 2009. Available at http://www.scottishmedicines.org/smc/files/Microsoft%20Word%20-%20calcipotriol%20and%20betamethasone%20dipropionate%20_Xamiol_%20FINAL%20July%202009%20for%20website.pdf [Accessed on 4 November 2009]
   Google Scholar
• Ware JE, Kosinski M, Turner-Bowker DM, et al. How to score version 2 of the SF-36® Health Survey. Lincoln, Rhode Island. QualityMetric Incorporated. 2000. see also www.SF-36.org/tools/SF36.shtml [Accessed 29 March 2010]
   Google Scholar
• Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92
   PubMed Web of Science ®Google Scholar
• Post hoc SF-6D analysis to derive 4-week utility data from study report MBL 0503INT; data on file, LEO Pharma
   Google Scholar
• Chen Y-F, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. 3 October 2005. West Midlands HTA Collaboration, The University of Birmingham. Available at http://www.nice.org.uk/nicemedia/pdf/Rheumatoid_arthritis_AR.pdf [Accessed 23 September 2009]
   Google Scholar
• De Jong EM. The course of psoriasis. Clin Dermatol 1997;15:687-92
   PubMed Web of Science ®Google Scholar
• Carey W, Glazer S, Gottlieb AB, et al. Relapse, rebound and psoriasis adverse events: An advisory group report. J Am Acad Dermatol 2006;54:S171-81
   PubMed Web of Science ®Google Scholar
• Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol 1999;41(Suppl):S25-8
   PubMedGoogle Scholar
• Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999;41:51-9
   PubMed Web of Science ®Google Scholar
• Berth-Jones J. Psoriasis. Medicine 2005;33:50-5
   Google Scholar
• Diprosone Cream and Ointment Summary of Product Characteristics. Available at http://www.medicines.org.uk/EMC/medicine/21278/SPC/Diprosone+Cream/ and http://www.medicines.org.uk/EMC/medicine/21279/SPC/Diprosone+Ointment/
   Google Scholar
• Betnovate Ointment Summary of Product Characteristics. Available at http://emc.medicines.org.uk/medicine/712/SPC/Betnovate+Ointment/
   Google Scholar
• Zaghloul S, Goodfield M. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004;140:408-14
   PubMed Web of Science ®Google Scholar
• MIMS March 2010
   Google Scholar
• Unit Costs of Health & Social Care 2009. Compiled by L Curtis. PSSRU. Available at www.pssru.ac.uk [Accessed 11 March 2010]
   Google Scholar
• Specialty costs and activity outpatient treatments by specialty by hospital; Dermatology outpatient treatment attendance, Report 043X, April 2008-March 2009 (released 24 November 2009), available at http://www.isdscotland.org/isd/4434.html (Accessed 11 March 2010)
   Google Scholar